A Study of Acute Respiratory Infections in Global Outpatient Setting

NCT ID: NCT05148780

Last Updated: 2025-02-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

245 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-20

Study Completion Date

2023-02-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the positivity rate of respiratory syncytial virus (RSV), influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in high-risk participants presenting with acute respiratory infections (ARIs) in outpatient settings during the influenza/RSV season and to evaluate the association between lower respiratory tract disease (LRTD) and ARI-related hospitalization in participants positive for RSV.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lower respiratory tract infections (LRTIs) are a major cause of mortality and morbidity worldwide with 2.3 million deaths in 2016 alone among all age groups, making it the sixth leading cause of mortality. The current study aims to assess the burden of RSV infections among adult participants presenting in outpatient settings, who are at high risk of complications or progression to severe disease due to their age or pre-existing comorbidities. Regional data from the United States (US), Europe, Middle East, and Asia (EMEA) and Asia-Pacific (APAC) will provide evidence on local RSV morbidity, mortality, medical resource utilization (MRU), standard of care, and quality of life in adults participants. A subset of participants positive for influenza virus and/or SARS-CoV-2 will also be enrolled, to allow for a comparative assessment of disease burden between the 3 viral respiratory pathogens. No study drug will be involved in this study. The total duration of the study for each participant will be a maximum of 3 months (+-1 week) from the date of enrollment. Safety will be assessed in the form of adverse events and serious adverse events related to study devices or procedures and for deaths regardless of causality.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Respiratory Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Acute Respiratory Infections (ARI) in Outpatient Setting

Participants presenting with ARIs in an outpatient setting who are at high risk of progressing to severe disease will be screened for viral respiratory pathogens (respiratory syncytial virus \[RSV\], Influenza, severe acute respiratory syndrome coronavirus 2 \[SARS-COV-2\]) by collecting a nasal swab. If a participant is positive for RSV and/or influenza virus and/or SARS-CoV-2 based on a study test or standard-of-care (SOC) polymerase chain reaction (PCR)-based test, the participant will be eligible for enrollment in the study in the home-based short-term and long-term follow-up phases.

Group Type OTHER

Nasal Swab Sample

Intervention Type DIAGNOSTIC_TEST

Nasal swab sample will be used to screen participants for detection of viral pathogens. No intervention or study drug will be administered as part of this study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nasal Swab Sample

Nasal swab sample will be used to screen participants for detection of viral pathogens. No intervention or study drug will be administered as part of this study.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Present to the general physician (GP)/specialist outpatient settings/respiratory clinics or in Emergency department (ED) settings with symptoms suggestive of a diagnosis of Acute Respiratory Infections (ARI)
* For inclusion in the home-based follow-up phases, must test positive for respiratory syncytial virus (RSV) and/or influenza and/or Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) per a molecular-based diagnostic assay (polymerase chain reaction \[PCR\]-based) using a nasal swab (nasopharyngeal or similar) sample. Co-infections are permitted to be enrolled in the study
* Must be able to read, understand, and complete questionnaires
* Must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study
* Willing and able to adhere to the specifications in this protocol

Exclusion Criteria

* Has a clinical condition other than those as specified in study protocol which, in the opinion of the investigator, could prevent, confound, or limit the protocol-specified assessments
* Received an investigational drug (including investigational vaccines) within 3 months before the start of the study or the first data collection time-point
* Is currently enrolled or plans to participate in another investigational study on RSV, influenza or SARS-CoV-2 during the current study
* Is, in the opinion of the investigator, unlikely to adhere to the requirements of the study, or is unlikely to complete the full course of observation
* Cannot communicate reliably with the investigator
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janssen Research & Development, LLC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Central Alabama Research

Birmingham, Alabama, United States

Site Status

Lakeview Clinical Research

Guntersville, Alabama, United States

Site Status

Synexus Clinical Research US Inc

Mesa, Arizona, United States

Site Status

Fiel Family and Sports Medicine Clinical Research Advantage

Phoenix, Arizona, United States

Site Status

Harrisburg Family Medical Center

Harrisburg, Arkansas, United States

Site Status

Innovative Research of West Florida, Incorporated

Clearwater, Florida, United States

Site Status

New Life Medical Research Center, Inc.

Hialeah, Florida, United States

Site Status

Best Quality Research Inc

Hialeah, Florida, United States

Site Status

PharmaDUX Clinical Medical Research, LLC

Medley, Florida, United States

Site Status

Homestead Associates in Research,Inc

Miami, Florida, United States

Site Status

Alma Clinical Research

Miami, Florida, United States

Site Status

Research Institute of South Florida Inc

Miami, Florida, United States

Site Status

Pines Care Research Center Inc

Pembroke Pines, Florida, United States

Site Status

Santos Research Center

Tampa, Florida, United States

Site Status

Columbus Regional Research Institute

Columbus, Georgia, United States

Site Status

IACT Health

Rincon, Georgia, United States

Site Status

Snake River Research, PLLC

Idaho Falls, Idaho, United States

Site Status

Washington University School Of Medicine

St Louis, Missouri, United States

Site Status

Montana Medical Research

Missoula, Montana, United States

Site Status

Healor Primary Care

Las Vegas, Nevada, United States

Site Status

Las Vegas Medical Research

Las Vegas, Nevada, United States

Site Status

Santa Rosa Medical Centers of Nevada

Las Vegas, Nevada, United States

Site Status

Urgent Care Clinical Trials at AFC Urgent Care

The Bronx, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

American Health Network, LLC

Charlotte, North Carolina, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

DayStar Clinical Research, Inc.

Akron, Ohio, United States

Site Status

Urgent Care Clinical Trials at AFC Urgent Care

Easley, South Carolina, United States

Site Status

Premier Family Physicians

Carrollton, Texas, United States

Site Status

Next Level Urgent Care

Corpus Christi, Texas, United States

Site Status

Southwest Family Medicine Associates

Dallas, Texas, United States

Site Status

Urgent Care Clinical Trials Fort Worth

Fort Worth, Texas, United States

Site Status

Southwest Clinical Trials

Houston, Texas, United States

Site Status

Renovatio Clinical

Magnolia, Texas, United States

Site Status

Benchmark Research

San Angelo, Texas, United States

Site Status

CCT Research at Olympus Family Medicine

Holladay, Utah, United States

Site Status

CCT Research at South Ogden Family Medicine

Ogden, Utah, United States

Site Status

Clinical Research Partners, LLC

Henrico, Virginia, United States

Site Status

IACT Health

Suffolk, Virginia, United States

Site Status

ALTA Clinical Research Inc.

Edmonton, Alberta, Canada

Site Status

CHU Grenoble

La Tronche, , France

Site Status

Hopital Edouard Herriot - CHU Lyon

Lyon, , France

Site Status

CHU Nimes Hopital Caremeau

Nîmes, , France

Site Status

Fujita Health University Hospital

Date-gun, , Japan

Site Status

Hanasaki Clinic

Kiyosu-shi, , Japan

Site Status

Miyagikoseikyokai Saka General Hospital

Shiogama, , Japan

Site Status

Klinik Kesihatan Putrajaya Presint 9

Kuala Lumpur, , Malaysia

Site Status

Klinik Kesihatan Kuang

Kuang, , Malaysia

Site Status

Klinik Kesihatan Masjid Tanah

Masjid Tanah, , Malaysia

Site Status

Hospital Miri

Miri, , Malaysia

Site Status

Gabinet Lekarski Pediatryczno-Alergologiczny

Bialystok, , Poland

Site Status

NEURO MEDIC Janusz Zbrojkiewicz Poradnia Wielospecjalistyczna

Katowice, , Poland

Site Status

ETG Lodz

Lodz, , Poland

Site Status

EMC Instytut Medyczny SA PL CERTUS

Poznan, , Poland

Site Status

NZOZ Leczniczo Rehabilitacyjny Osrodek Medycyny Rodzinnej

Wroclaw, , Poland

Site Status

Inje University Busan Paik Hospital

Busan, , South Korea

Site Status

Korea University Ansan Hospital

Gyeonggi-do, , South Korea

Site Status

Gachon University Gil Medical Center

Incheon, , South Korea

Site Status

Hallym University Kangnam Sacred Heart Hospital

Seoul, , South Korea

Site Status

Cs Algeciras Norte

Algeciras, , Spain

Site Status

Hosp. Gral. Univ. de Alicante

Alicante, , Spain

Site Status

Eap Sardenya

Barcelona, , Spain

Site Status

Cap Apenins - Montigala

Caldes Montbui Canovelles, , Spain

Site Status

Cap Canet de Mar

Canet de Mar, , Spain

Site Status

Hosp. Clinico San Carlos

Madrid, , Spain

Site Status

Kaohsiung Medical University Chung Ho Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

Taipei Medical University Shuang Ho Hospital

New Taipei City, , Taiwan

Site Status

Taipei Medical University

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

Tri-Service General Hospital

Taipei, , Taiwan

Site Status

Taipei Municipal Wanfang Hospital

Taipei, , Taiwan

Site Status

The Adam Practice

Metropolitan Borough of Wirral, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada France Japan Malaysia Poland South Korea Spain Taiwan United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NOPRODRSV4002

Identifier Type: OTHER

Identifier Source: secondary_id

CR109104

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Infection Watch Study
NCT04623047 COMPLETED
Respiferon Project
NCT06017310 UNKNOWN